CytoTools : financing.pdf

• The shareholders of the DermaTools Biotech GmbH decided unanimously to adopt three options for further financing of the clinical developments

• The three financing options which were presented are to be negotiated concurrently and one is to be completed in the first quarter of 2017.

• The new Chief Medical Officer of the CytoTools AG is preparing a new clinical strategy

Darmstadt, 12.01.2017 - The shareholders of the DermaTools Biotech GmbH, decided unanimously, at a shareholders' meeting, to implement one of three proposed financing options in the first quarter of 2017. The shareholders were presented with proposals for three different scenarios for the further financing, and thus the repeat of the clinical trial. One of the possible variations includes the capital measures (convertible bond/capital increase) which were agreed by the shareholders at the annual general meeting of the CytoTools AG in August. Two further financing options relate specifically to the DermaTools Biotech GmbH. The shareholders agreed that after all operative prerequisites for the clinical trials have now been fulfilled, the financing solution should be realised in the coming weeks.

After successful financing, the DermaTools Biotech GmbH will continue to pursue the clinical development of the main product DermaPro®. To this end, a concept is being developed by the new Chief Medical Officer of the CytoTools AG, Dr. Wilfried Hauke: this is largely based on the data obtained to date. Details on this concept will be presented already in January 2017 by the CytoTools AG.

After the successful realisation of the financing concept, the resumption of the final clinical trials will commence; the necessary preparatory work in manufacturing and clinical planning - including all the regulatory provisions - have already largely been completed.

Dr. Freyberg, the responsible CEO, commented: "We are now working to fulfil the prerequisites for a resumption of clinical trials in Europe. We hope that one of the financing concepts can be realised quickly, so that we do not lose further valuable time before the product launch. Here, a key role will be played by the new clinical strategy which Dr. Hauke will be presenting in the coming weeks."

This press release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future- oriented statements made. CytoTools is not obligated to update these future-oriented statements.

About CytoTools:

The CytoTools AG (formally CytoTools GmbH) is a biotechnology and holding company and as such holds investments in its subsidiaries performing product development in the pharmaceutical and medical field. These are DermaTools Biotech GmbH (57%) - therapy field: dermatology, urology, and CytoPharma GmbH (42%) - therapy field cardiovascular disease and cancer. The complete know-how is protected by corresponding fundamental patents, which are maintained worldwide, and is passed on to the subsidiaries in the form of worldwide exclusive licenses.

CytoTools AG

Dr. Mark Andre Freyberg Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: freyberg@cytotools.de